Aligos Therapeutics, Inc.
ALGS
$7.35
-$0.31-3.99%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 43.88% | -44.59% | -55.88% | -60.16% | -76.29% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 43.88% | -44.59% | -55.88% | -60.16% | -76.29% |
| Cost of Revenue | 2.15% | -21.03% | -28.77% | -37.39% | -23.61% |
| Gross Profit | 0.52% | 19.63% | 26.47% | 34.71% | 10.96% |
| SG&A Expenses | 4.04% | -9.25% | -10.40% | -19.01% | -24.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.00% | -3.15% | -10.50% | -18.95% | -9.77% |
| Operating Income | -10.79% | 1.31% | 7.60% | 15.41% | -0.96% |
| Income Before Tax | -69.60% | 81.76% | -12.35% | 2.23% | 46.45% |
| Income Tax Expenses | 68.00% | -5.14% | 13.50% | 63.21% | -55.13% |
| Earnings from Continuing Operations | -69.59% | 81.56% | -12.36% | 2.05% | 46.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -69.59% | 81.56% | -12.36% | 2.05% | 46.52% |
| EBIT | -10.79% | 1.31% | 7.60% | 15.41% | -0.96% |
| EBITDA | -10.74% | 1.22% | 7.41% | 15.29% | -1.51% |
| EPS Basic | 14.79% | 93.48% | 6.14% | 39.18% | 68.40% |
| Normalized Basic EPS | 14.90% | 93.61% | 5.06% | 38.83% | 67.98% |
| EPS Diluted | 50.12% | 58.87% | -48.09% | 4.12% | 46.01% |
| Normalized Diluted EPS | 16.37% | 92.76% | 3.72% | 37.96% | 67.42% |
| Average Basic Shares Outstanding | 52.48% | 57.68% | 48.51% | 62.14% | 84.13% |
| Average Diluted Shares Outstanding | 50.77% | 58.83% | 49.72% | 63.63% | 86.22% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |